Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer

Hwee‐Yong ‐Y Yap, Gabriel N. Hortobagyi, George R. Blumenschein, Charles K. Tashima, Aman U. Buzdar, Allan N. Krutchik, Robert S. Benjamin, Jordan U. Gutterman, Gerald P. Bodey

Research output: Contribution to journalArticle

Abstract

Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85% and a median duration of response of 25 months. Response rate of 69% and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87% and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)333-341
Number of pages9
JournalJournal of Surgical Oncology
Volume12
Issue number4
DOIs
StatePublished - 1979

Fingerprint

Ovariectomy
Breast Neoplasms
Tegafur
Levamisole
Mycobacterium bovis
Immunotherapy
Doxorubicin
Cyclophosphamide

Keywords

  • combined chemoimmunotherapy for breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Yap, HY. Y., Hortobagyi, G. N., Blumenschein, G. R., Tashima, C. K., Buzdar, A. U., Krutchik, A. N., ... Bodey, G. P. (1979). Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. Journal of Surgical Oncology, 12(4), 333-341. https://doi.org/10.1002/jso.2930120407

Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. / Yap, Hwee‐Yong ‐Y; Hortobagyi, Gabriel N.; Blumenschein, George R.; Tashima, Charles K.; Buzdar, Aman U.; Krutchik, Allan N.; Benjamin, Robert S.; Gutterman, Jordan U.; Bodey, Gerald P.

In: Journal of Surgical Oncology, Vol. 12, No. 4, 1979, p. 333-341.

Research output: Contribution to journalArticle

Yap, HYY, Hortobagyi, GN, Blumenschein, GR, Tashima, CK, Buzdar, AU, Krutchik, AN, Benjamin, RS, Gutterman, JU & Bodey, GP 1979, 'Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer', Journal of Surgical Oncology, vol. 12, no. 4, pp. 333-341. https://doi.org/10.1002/jso.2930120407
Yap, Hwee‐Yong ‐Y ; Hortobagyi, Gabriel N. ; Blumenschein, George R. ; Tashima, Charles K. ; Buzdar, Aman U. ; Krutchik, Allan N. ; Benjamin, Robert S. ; Gutterman, Jordan U. ; Bodey, Gerald P. / Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. In: Journal of Surgical Oncology. 1979 ; Vol. 12, No. 4. pp. 333-341.
@article{3c6f436259a94a45bf52a2acadab5d49,
title = "Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer",
abstract = "Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85{\%} and a median duration of response of 25 months. Response rate of 69{\%} and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87{\%} and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.",
keywords = "combined chemoimmunotherapy for breast cancer",
author = "Yap, {Hwee‐Yong ‐Y} and Hortobagyi, {Gabriel N.} and Blumenschein, {George R.} and Tashima, {Charles K.} and Buzdar, {Aman U.} and Krutchik, {Allan N.} and Benjamin, {Robert S.} and Gutterman, {Jordan U.} and Bodey, {Gerald P.}",
year = "1979",
doi = "10.1002/jso.2930120407",
language = "English (US)",
volume = "12",
pages = "333--341",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer

AU - Yap, Hwee‐Yong ‐Y

AU - Hortobagyi, Gabriel N.

AU - Blumenschein, George R.

AU - Tashima, Charles K.

AU - Buzdar, Aman U.

AU - Krutchik, Allan N.

AU - Benjamin, Robert S.

AU - Gutterman, Jordan U.

AU - Bodey, Gerald P.

PY - 1979

Y1 - 1979

N2 - Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85% and a median duration of response of 25 months. Response rate of 69% and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87% and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.

AB - Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85% and a median duration of response of 25 months. Response rate of 69% and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87% and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.

KW - combined chemoimmunotherapy for breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0018687866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018687866&partnerID=8YFLogxK

U2 - 10.1002/jso.2930120407

DO - 10.1002/jso.2930120407

M3 - Article

C2 - 392197

AN - SCOPUS:0018687866

VL - 12

SP - 333

EP - 341

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -